Faculty Profile, National Health Research Institutes, Taiwan

Faculty Profiles


Shiow-Ju Lee, Ph.D.

Associate Investigator
Institute of Biotechnology and Pharmaceutical Research
slee@nhri.org.tw

EDUCATION

  • Ph.D., Biochemistry & Molecular Biology, University of Texas, Southwestern Medical Center, USA, 1998
  • M.S., Plant Pathology, National Taiwan University, Taiwan, 1989

    PROFESSIONAL EXPERIENCES

  • Associate Investigator, Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Taiwan (2006-present)
  • Assistant Investigator, Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Taiwan (2002-2006)
  • Head of High Throughput Screening Core for Drug discovery, Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Taiwan (2002-2005)
  • Research Scientist, Invitrogen, Invitrogen co. (2000-2002)
  • Associate Research Scientist, Invitrogen co./ Research Genetics Inc. (1999-2000)

    RESEARCH INTERESTS

    Dr. Lee's biology lab works on "drug discovery and development for anti-cancerous and anti-inflammatory diseases" as well as "molecular pharmacology, biochemistry & molecular biology, and chemical biology."

    RESEARCH ACTIVITIES & ACCOMPLISHMENTS

    Dr. Lee had made efforts in drug discovery project for anti-cancers, anti-coronoviruses, anti-inflammatory diseases, and identified classes of lead compounds. With the obtained compounds, Dr. Lee has focused on developing phenanthroindolizidines and derived dibenzoquinolines into therapeutic agents for anti-inflammatory related diseases, anti-coronaviruses, and anti-cancers. These results have been published and obtained patents in US and other countries.
    Lately, Dr. Lee is also engaged in discovery and development of natural products for therapeutic agents and related studies. Moreover, a drug discovery project was just launched for development of anti-cancer agents through interfering glutaminolysis in cancer cells.

    SELECTED PUBLICATIONS

    1.Yang CW, Lee YZ, Hsu HY, Wu CM, Chang HY, Chao YS, Lee SJ*. c-Jun-mediated anti-cancer mechanisms of tylophorine. 2013. Carcinogensis, doi: 10.1093/carcin/bgt039. First published online: February 5, 2013. (Corresponding author)
    2.Chang HS, Chiang MY, Hsu HY, Yang CW, Lee SJ*, and Chen IS*. Cytotoxic Cardenolide Glycosides from the Root of Reevesia formosana. Phytochemistry, 2013, 87:86-95. (Co-corresponding author)
    3.Lee YZ, Yang CW, Hsu HY, Qiu YQ, Yeh TK, Chang HY, Chao YS, Lee SJ*. Synthesis and Biological Evaluation of Tylophorine-Derived Dibenzoquinolines as Orally Active Agents–Exploration of the Role of Tylophorine E Ring on Biological Activity. Journal of Medicinal Chemistry. 2012, 55: 10363-77. (Corresponding author)
    4.Lee YZ,#, Huang CW,#, Yang CW, Hsu HY, Kang IJ, Chao YS, Chen IS, Chang HY, and Lee SJ*. Isolation and evaluation of biological activities of phenanthroindolizidine and septicine alkaloids from Formosa Tylophora ovata. Planta Medica, 2011; 77: 1932–1938. (Corresponding author)
    5.Yang CW, Lee YZ, Kang IJ, Barnard DL, Jan JT, Lin D, Huang CW, Yeh TK, Chao YS, Lee SJ*. (Corresponding author) Identification of Phenanthroindolizines and Phenanthroquinolizidines as Novel Potent Anti-Coronaviral Agents for Porcine Enteropathogenic Coronavirus Transmissible Gastroenteritis Virus and Human Severe Acute Respiratory Syndrome Coronavirus. Antiviral Research, 2010, 88:160-168. (Corresponding author)
    6.Wu CM, Yang CW, Lee YZ, Chuang TH, Wu PL, Chao YS, Lee SJ*. Tylophorine arrests carcinoma cells at G1 phase by downregulating cyclin A2 expression. Biochemical and Biophysical Research Communications 2009, 386 (1), 145-150. (Corresponding author)
    7.Yang CW, Yang YN, Liang PH, Chen CM, Chen WL, Chang HY, Chao YS and Lee SJ*. Identification of Novel Small-Molecule Inhibitors of Transmissible Gastroenteritis Virus. Antimicrobial Agents and Chemotherapy, 51 (11):3924-3931, 2007. (Corresponding author)
    8.Yang CW, Chuang TH, Wu PL, Huang WH and Lee SJ*. Anti-Inflammatory Effects of 7-Methoxycryptopleurine and Structure-Activity Relations of Phenanthroindolizidines and Phenanthroquinolizidines. Biochemical and Biochemical and Biophysical Research Communications, 354(4):942-8, 2007. (Corresponding author)
    9.Yang CW, Chen WL, Tseng HY, Wu PL and Lee SJ*. Anti-inflammatory Mechanisms of Phenanthroindolizidine Alkaloids. Molecular Pharmacology, 69(3):749-758, 2006.
    10.Chuang TH, Shiow-Ju Lee, Yang CW and Pei-Lin Wu*. Expedient Synthesis and Structure-Activity Relationships of Phenanthroindolizidine and Phenanthroquinolizidine Alkaloids . Organic & Biomolecular Chemistry. 2006 (4), 860-867.
    11.Lu IL, Lee SJ, Tsu H, Wu SY, Kao KH, Chien CH, Chang YY, Chen YS, Cheng JH, Chang CN, Chen TW, Chang SP, Chen X and Jiaang WT. Glutamic acid analogues as potent dipeptidyl peptidase IV and 8 inhibitors. Bioorganic and Medicinal Chemistry Letters, 15?13??3271-3275,July 1,2005.(Co-first author)
    12.Tseng HY, Wu SH, Huang WH, Wang SF, Yang YN, Mahindroo N, Hsu T, Jiaang WT and Lee SJ*. Benzothiazolium Compounds: Novel Classes of Inhibitors That Suppress the Nitric Oxide Production in RAW264.7 Cells Stimulated by LPS/IFN

    PATENT

  • ROC Patent No. 94120175. "???吲哚????"; granted Nov. 27th, 2007.
  • US, Patent No. I 29004. "Phenanthroindolizidine alkaloids"; granted Nov. 21st, 2007.